30 patents
Utility
Anti-Dectin-2 Antibodies
21 Dec 23
The invention relates to dendritic cell-associated C-type lectin 2 (Dectin-2) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof.
Shelley Erin ACKERMAN, David DORNAN, Karla A. HENNING, Justin A. KENKEL
Filed: 21 Jul 23
Utility
Thienoazepine Immunoconjugates, and Uses Thereof
26 Oct 23
The invention provides immunoconjugates of Formula I comprising an antibody linked by conjugation to one or more thienoazepine derivatives.
Romas Kudirka, Brian Safina
Filed: 6 Mar 23
Utility
Elastase-substrate, Peptide Linker Immunoconjugates, and Uses Thereof
21 Sep 23
The invention provides immunoconjugates of Formula I comprising a cell-binding agent linked by conjugation to one or more immunostimulatory moieties where the linker is a substrate for elastase.
David DORNAN, Romas KUDIRKA, Brian SAFINA, Matthew ZHOU
Filed: 7 May 21
Utility
Anti-Dectin-2 antibodies
12 Sep 23
The invention relates to dendritic cell-associated C-type lectin 2 (Dectin-2) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof.
Shelley Erin Ackerman, David Dornan, Karla A. Henning, Justin A. Kenkel
Filed: 3 Feb 22
Utility
Macromolecule-supported Thienoazepine Compounds, and Uses Thereof
17 Aug 23
The invention provides macromolecule-supported compounds of Formula I comprising a macromolecular support linked by conjugation to one or more thienoazepine derivatives.
Romas KUDIRKA, Brian SAFINA
Filed: 23 Oct 20
Utility
Thienoazepine immunoconjugates, and uses thereof
23 May 23
The invention provides immunoconjugates of Formula I comprising an antibody linked by conjugation to one or more thienoazepine derivatives.
Romas Kudirka, Brian Safina
Filed: 23 Oct 20
Utility
Antibody Adjuvant Conjugates
13 Apr 23
The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker.
Michael Nathaniel Alonso, Edgar George Engleman, Shelley Erin Ackerman, Justin Kenkel, Arthur Lee, David Y. Jackson
Filed: 8 Aug 22
Utility
ANTI-PD-L1 Antibodies
23 Mar 23
The invention relates to programmed death-ligand 1 (PD-L1) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof.
Michael N. ALONSO, David DORNAN, Karla HENNING, Justin KENKEL, Marcin KOWANETZ, Heidi LEBLANC, William MALLET
Filed: 21 Jan 21
Utility
ANTI-PD-L1 Antibodies
2 Mar 23
The invention relates to programmed death-ligand 1 (PD-L1) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof.
Michael N. ALONSO, David DORNAN, Karla HENNING, Justin KENKEL, Marcin KOWANETZ, Heidi LEBLANC, William MALLET
Filed: 21 Jan 21
Utility
Antibody adjuvant conjugates
10 Jan 23
The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker.
Michael Nathaniel Alonso, Edgar George Engleman, Shelley Erin Ackerman, Justin Kenkel, Arthur Lee, David Y. Jackson
Filed: 3 Sep 21
Utility
Amide-linked, Aminobenzazepine Immunoconjugates, and Uses Thereof
3 Nov 22
The invention provides immunoconjugates of Formula I comprising an antibody linked by conjugation to one or more 8-amido-2-aminobenzazepine derivatives.
Romas KUDIRKA, Brian SAFINA, Matthew ZHOU
Filed: 29 Sep 20
Utility
Immunoconjugates Targeting HER2
3 Nov 22
Shelley Erin Ackerman, Michael N. Alonso, David Y. Jackson, Arthur Lee, Edgar George Engleman
Filed: 30 Jun 22
Utility
Immunoconjugate Synthesis Method
3 Nov 22
Puneet Anand, David Dornan, Romas Kudirka, Richard P. Laura, Arthur Lee, Brian Safina, Matthew Zhou
Filed: 4 Sep 20
Utility
Aminoquinoline Compounds, Immunoconjugates, and Uses Thereof
6 Oct 22
The invention provides immunoconjugates of Formula (I) comprising an antibody linked by conjugation to one or more aminoquinoline derivatives.
Romas KUDIRKA, Brian SAFINA, Matthew ZHOU
Filed: 2 Sep 20
Utility
Macromolecule-supported Aminobenzazepine Compounds
6 Oct 22
The application provides macromolecule-supported compounds of Formula I or III comprising a macromolecular support linked by conjugation to one or more aminobenzazepine derivatives.
Shelley Erin Ackerman, Michael N. Alonso, Romas Kudirka, Arthur Lee, Brian Safina, Matthew Zhou
Filed: 12 Jun 20
Utility
Immunoconjugates targeting HER2
2 Aug 22
Shelley Erin Ackerman, Michael N. Alonso, David Y. Jackson, Arthur Lee, Edgar George Engleman
Filed: 2 Sep 21
Utility
Immunoconjugates Targeting PD-L1
21 Jul 22
The invention provides an immunoconjugate of formula (I) or (II).
Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Justin Kenkel, Romas Kudirka, Arthur Lee, Brian Safina, Matthew Zhou, Edgar George Engleman
Filed: 13 Mar 20
Utility
Immunoconjugates Targeting HER2
21 Jul 22
The invention provides an immunoconjugate of formula (I) or (II).
Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Romas Kudirka, Arthur Lee, Brian Safina, Matthew Zhou, Edgar George Engleman
Filed: 13 Mar 20
Utility
Anti-cea Immunoconjugates, and Uses Thereof
23 Jun 22
The invention provides immunoconjugates of Formula I comprising an anti-CEA antibody linked by conjugation to one or more 8-Het-2-aminobenzazepine derivatives.
Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Marcin Kowanetz, Romas Kudirka, Arthur Lee, William Mallet, Brian Safina, Matthew Zhou
Filed: 9 Dec 21
Utility
Macromolecule-Supported TLR Agonists
12 May 22
Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Justin Kenkel, Romas Kudirka, Arthur Lee, Brian Safina, Matthew Zhou, Edgar George Engleman
Filed: 13 Mar 20